

PERCHERON RECEIVES \$2.35 MILLION RESEARCH AND DEVELOPMENT TAX INCENTIVE REBATE

Melbourne, Australia – 8 October 2024: Percheron Therapeutics Limited (ASX: PER) ('the Company'), an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce that it has received a \$2.35 million R&D Tax Incentive rebate for the 2024 financial year.

The rebate relates to expenditure incurred on eligible R&D activities undertaken in Australia and overseas. Funds received will be applied directly to the ongoing international phase IIb clinical trial of avicursen in Duchenne muscular dystrophy.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in December CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorised for release to the Australian Securities Exchange by the Board of Directors.
